Stock

Elevance Health

ELV
40
Medical - Healthcare Plans · Healthcare
Also trades as: 0HG8.L GBP 4.44 (-0.83%)
Price
$442.90
-2.38 (-0.53%)
Market Cap
$96.05B
Winston Score
40
Winston is serious
Mixed quality — meaningful strengths and weaknesses.
Data as of Oct 23, 2026 · filings through Sep 30, 2026

§How the score breaks down

Quality
Mixed
11/30
Growth
Weak
4/20
Cash Flow
Strong
7/10
Stability
Strong
8/10
Valuation
Strong
8/10
Ownership
Weak
1/15
Dividends
Weak
1/5

40 of 100 counted points = Winston Score 40.

Share count falling — buybacks

−10.1% over 4y

The company has reduced its share count over this period, returning value to shareholders through buybacks.

Diluted shares outstanding: 246.8M (2021) → 221.8M (2025)

§Winston Score History

The full picture

Elevance Health is one of the largest health insurance companies in the United States. It sells medical, dental, and vision insurance plans to individuals, families, employers, and government programs like Medicaid and Medicare. The company operates the Blue Cross Blue Shield brand in 14 states, which is one of the most recognized names in American healthcare.

Elevance makes money by collecting monthly premiums from members and then paying out claims when those members use medical services. It serves roughly 45 million members across all 50 states, though its core insurance business is concentrated in states where it holds Blue Cross Blue Shield licenses. The company also runs a growing healthcare services segment called Carelon, which provides pharmacy, behavioral health, and care management services. The main risk Elevance faces is rising medical costs — when members use more healthcare than expected, profit margins shrink quickly, as seen in recent quarters where higher utilization pressured earnings.

Politician Trades

16 trades / 12mo

9 Congressional buys and 7 sells on ELV in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+1.4% YoY

YoY Growth Rate

Slow revenue growth

Reported EPS Growth

+18.4% YoY

Quarterly reporting periods ended:

30 Sept 2025: $5.32

30 Sept 2026: $6.30

Reported/statutory EPS, not adjusted or underlying earnings. One-off items can affect this figure. Provider rounding can affect the growth rate.

YoY Growth Rate

Reported EPS increased year over year

R&D Spend

$0/ year

0.0% of revenue

Below sector average (18%)

Research and development spending

Insider Activity

0.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$23.1B cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

Elevance Health is growing revenue at 1% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
15.6%
Thin — 15.6% gross margin
Profit after running costs
Operating Margin
4.2%
Thin — 4.2% operating margin
Return on the money invested
ROCE
16.6%
Strong — 16.6% return on capital

ROIC between 15% and 25%. Every dollar invested in the business earns 15 to 25 cents back per year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
+3.6%
Slow sales growth (+3.6% YoY)
Profit growth
EPS YoY
-4.2%
Earnings shrinking (-4.2% YoY)

Slight earnings drop. Typical near a cyclical low.

How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
148%
Turns 148% of profit into real cash
Spare cash per sale
FCF Margin
3.2%
Thin free cash flow (3.2%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.01
Conservative — low debt load (0.01)
Covers its interest
Interest Cover
6.56x
Adequate interest coverage (6.6x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
18.9x
Fair value — P/E 18.9

P/E in the normal range. Price is roughly $15 for every $1 of yearly profit.

Cheaper or dearer next year
P/E vs Forward
+6.1
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (18.9 → 12.8)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
1.61%
Small dividend — 1.61% yield

Modest yield. The bulk of any return needs to come from price appreciation.

Dividend record
Dividend Growth
+1.6%
Dividend flat
Payout Ratio
29%
no trend
Pays out a modest share of profit and keeps the rest to reinvest. Room to keep paying through a weak year.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial